Table 2.
Baseline characteristics of patients under antiplatelet and anticoagulant drugs.
| Characteristics | No antithrombotic | Antiplatelet user1 | Anticoagulant user1 |
|---|---|---|---|
| (n = 170) | (n = 73) | (n = 44) | |
| Age, y, mean (SD) | 56.1 (18.7) | 72.40 (12.7)2 | 71.8 (13.4)2 |
| Female sex, n (%) | 109 (64.1) | 44 (60.3) | 22 (50.0) |
| Visible OGIB, n (%) | 30 (17.6) | 13 (17.8) | 10 (22.7) |
| Hemoglobin, g/dL (SD) | 9.7 (2.1) | 8.7 (1.9)2 | 8.7 (1.8)2 |
| Comorbidity | |||
| Diabetes mellitus, n (%) | 34 (20.0) | 36 (49.3)2 | 17 (38.6) |
| Arterial hypertension, n (%) | 69 (40.6) | 53 (72.6)2 | 29 (65.9)2 |
| Ischaemic heart disease, n (%) | 22 (12.9) | 22 (30.1)2 | 17 (38.6)2 |
| Chronic kidney disease, n (%) | 14 (8.2) | 10 (13.7) | 8 (18.2) |
1Thirteen patients were treated with both antiplatelet and anticoagulant drugs.
2 P < 0.05.